21
Simons, Joost J.M., Vida, Nora, Westra, Tjalke A., Postma, Maarten J.
Veröffentlicht in: Vaccine ; volume 38, issue 30, page 4687-4694 ; ISSN 0264-410X;
2020
Veröffentlicht in: Vaccine ; volume 38, issue 30, page 4687-4694 ; ISSN 0264-410X;
2020
22
Rozenbaum, Mark H., van Hoek, Albert Jan, Hak, Eelko, Postma, Maarten J.
Veröffentlicht in: Rozenbaum , M H , van Hoek , A J , Hak , E & Postma , M J 2010 , ' Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar (R)) ' , Vaccine , vol. 28 , no. 12 , pp. 2367-2369 . https://doi.org/10.1016/j.vaccine.2010.01.005;
2010
Veröffentlicht in: Rozenbaum , M H , van Hoek , A J , Hak , E & Postma , M J 2010 , ' Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar (R)) ' , Vaccine , vol. 28 , no. 12 , pp. 2367-2369 . https://doi.org/10.1016/j.vaccine.2010.01.005;
2010
23
Luttjeboer, Jos, Setiawan, Didik, Cao, Qi, Daemen, Toos CAHH, Postma, Maarten J.
Veröffentlicht in: Luttjeboer , J , Setiawan , D , Cao , Q , Daemen , T CAHH & Postma , M J 2016 , ' Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands ' , Vaccine , vol. 34 , no. 50 , pp. 6381-6387 . https://doi.org/10.1016/j.vaccine.2016.10.019;
2016
Veröffentlicht in: Luttjeboer , J , Setiawan , D , Cao , Q , Daemen , T CAHH & Postma , M J 2016 , ' Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands ' , Vaccine , vol. 34 , no. 50 , pp. 6381-6387 . https://doi.org/10.1016/j.vaccine.2016.10.019;
2016
24
de Jong, Lisa A, Dvortsin, Evgeni, Janssen, Kristel J., Postma, Maarten J.
Veröffentlicht in: de Jong , L A , Dvortsin , E , Janssen , K J & Postma , M J 2017 , ' Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands ' , Clinical Therapeutics , vol. 39 , no. 2 , pp. 288-302 . https://doi.org/10.1016/j.clinthera.2016.12.012;
2017
Veröffentlicht in: de Jong , L A , Dvortsin , E , Janssen , K J & Postma , M J 2017 , ' Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands ' , Clinical Therapeutics , vol. 39 , no. 2 , pp. 288-302 . https://doi.org/10.1016/j.clinthera.2016.12.012;
2017
25
Wilschut, Jan C, Bruijning-Verhagen, Patricia C J L, Postma, Maarten J
Veröffentlicht in: Wilschut , J C , Bruijning-Verhagen , P C J L & Postma , M J 2022 , ' Rotavirusvaccinatie voor alle jonge kinderen ' , Nederlands Tijdschrift voor Geneeskunde , vol. 166 , D6337 . < https://www.ntvg.nl/artikelen/rotavirusvaccinatie-voor-alle-jonge-kinderen >;
2022
Veröffentlicht in: Wilschut , J C , Bruijning-Verhagen , P C J L & Postma , M J 2022 , ' Rotavirusvaccinatie voor alle jonge kinderen ' , Nederlands Tijdschrift voor Geneeskunde , vol. 166 , D6337 . < https://www.ntvg.nl/artikelen/rotavirusvaccinatie-voor-alle-jonge-kinderen >;
2022
26
27
28
de Vries, Folgerdiena M., Denig, Petra, Visser, Sipke T., Hak, Eelko, Postma, Maarten J.
Veröffentlicht in: de Vries , F M , Denig , P , Visser , S T , Hak , E & Postma , M J 2014 , ' Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands ' , Value in Health , vol. 17 , no. 2 , pp. 223-230 . https://doi.org/10.1016/j.jval.2013.12.010;
2014
Veröffentlicht in: de Vries , F M , Denig , P , Visser , S T , Hak , E & Postma , M J 2014 , ' Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands ' , Value in Health , vol. 17 , no. 2 , pp. 223-230 . https://doi.org/10.1016/j.jval.2013.12.010;
2014
29
van der Schans, Jurjen, Kotsopoulos, Niko, Hoekstra, Pieter J., Hak, Eelko, Postma, Maarten J.
Veröffentlicht in: van der Schans , J , Kotsopoulos , N , Hoekstra , P J , Hak , E & Postma , M J 2015 , ' Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate ' , PLoS ONE , vol. 10 , no. 5 , e0127237 . https://doi.org/10.1371/journal.pone.0127237;
2015
Veröffentlicht in: van der Schans , J , Kotsopoulos , N , Hoekstra , P J , Hak , E & Postma , M J 2015 , ' Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate ' , PLoS ONE , vol. 10 , no. 5 , e0127237 . https://doi.org/10.1371/journal.pone.0127237;
2015
30